Gapping up
In reaction to strong earnings/guidance: BORN +50.3%, ERII +18.9%, GRO +12.2%, AV +9.8% (also upgraded to Buy from Hold at Panmure Gordon), ORAN +9%, TKMR +8.3%, (also receives Fast Track designation from FDA for its anti-Ebola viral therapeutic), RNET +8.2%, NEON +7.1%, LOGI +6.1%, ZGNX +4.7%, RGEN +4.6%, VVTV +4.3%, SNSS +4.3%, ( sponsor study: combination of vosaroxin and decitabine is effective and well tolerated in older patients with AML and high-risk MDS), SPTN +3.1%, (light volume), PCOM +3.1%, DRIV +2.8%, ( announces repurchases of convertible debt; sees Q1 adjusted EPS of $0.08-0.12 vs $0.09 Capital IQ Consensus Estimate, sees FY14 adjusted EPS of $0.41-0.51 vs $0.39 Capital IQ Consensus Estimate), CIEN +1.7%, SMTC +1.6%, BITA +1.2%, ESPR +0.7% (thinly traded), JOY +0.6%, GA +0.4%.
A few financial related names showing strength: SAN +1.3%, DB +1.1%, CS +1%, BAC +0.6% (to offer checking account with $4.95/monthly fee, according to reports), BBVA +0.3%.
Other news: SGMO +19.8% (reported first-in-man study of genome editing using Sangamo's ZFN technology published in NEJM ), PXLW +12.5% (disclosed established direct relationships with companies that manufacture high-end display systems; disclosed sales to top customers including Apple), BIOD +11.1% (announces commercial manufacturing agreement with Emergent BioSolutions for glucagon rescue product), DDXS +10.6% (announces exclusive U.S. licensing deal with Thermo Fisher Scientific), TKMR +9.6% (receives fast track designation from FDA for Anti-Ebola Viral Therapeutic), RGSE +6.3% (still checking), PSTI +5.9% (FDA approves Pluristem's commercial scale cell manufacturing process , OMER +4.9% (reports additional positive data from its OMS824 Phase 2a schizophrenia clinical trial; significantly higher drug exposure achieved with continued tolerability), NBS +4.5% (ticking higher, entered into a sponsored research collaboration with Massachusetts Eye and Ear/Schepens Eye Research Institute, an affiliate of Harvard Medical School), SODA +4.4% (speculation of new investor stake), QUNR +4.3% (has received $300 mln investment from Bidu, according to reports), FCEL +3.5% (continued momentum), PPHM +2.8% (continued strength), VRNS +2.7% ( announces closing of its initial public offering of 4.8 mln shares of its common stock at a price to the public of $22.00), XGTI +2.4% (following yesterday's 130% move higher), CSTM +1.8% (announces secondary offering by selling shareholder), DRI +1.8% (has canceled out of investor meeting amid activist pressure, according to reports), CSIQ +1.5% ( Receives CAD48 Million Financing from Manulife), ARR +1.4% (authorizes co to increase the size of its existing stock repurchase authorization from $100 mln in value of its outstanding shares to an authorization for future repurchases of up to 50 mln shares of its outstanding common stock), PHG +1.4% (still checking), LBTYA +1.2% (still checking), GEVA +2.4% (announces pricing of 2 mln offering of common stock at $105.75 per share), ENDP +1.2% (announces FDA Approved AVEED), NVS +1.1% (announces Xolair approved in EU as first and only licensed therapy for chronic spontaneous urticaria patients unresponsive to antihistamines, ASC +1.1% (priced upsized public offering of 7,000,000 shares of its common stock at $13.50 per share (previously announced 6,000,000 shares), APC +1% (trading higher following positive Cramer mention), TSLA +0.9% (Model S has received sizable pre orders in China, according to reports), LNG +2.1% (WSJ discusses that House Republicans are pressing Obama to approve natural gas exports).
Analyst comments: AXLL +5.9% (upgraded to Buy from Neutral at Goldman; tgt raised to $60 from $45), DRTX +3.6% (initiated with a Buy at ROTH Capital; tgt $20 ), HA +3% (upgraded to Buy from Hold at Deutsche Bank),BIIB +2.1% (Biogen Idec upgraded to Outperform from Mkt Perform at BMO Capital Mkts; tgt raised to $422 from $286), NM +1% (upgraded to Buy from Hold at Stifel), NS +0.7% (upgraded to Overweight from Neutral at JP Morgan; tgt raised to $60 from $51)